The lifting of the FDA’s clinical hold on Neurizon’s drug will pave the way for its investigation in the HEALEY-ALS trial.

Italy-based biotech firm NanoPhoria Bioscience has announced the initial closing of its Series A funding round, raising ...

Venture financing for messenger ribonucleic acid (mRNA)-based innovator vaccines declined by 82% from $510m in 2023 to $90m ...

Chiesi Group and Arbor have formed an exclusive partnership and licensing deal for the latter’s investigational gene editing ...

Support services are fundamentally important to CDMS vendor selection. Consider the story of this complex rescue study when ...

Induced pluripotent stem cells (iPSCs) have the potential to usher in a new era of transformative medical treatments, capable ...

This culminated in a $500m funding cut to mRNA vaccine research funding, impacting around 22 projects being run at the ...

AstraZeneca and Daiichi's Datroway offered significant improvements to overall survival (OS) in immunotherapy-ineligible ...

The completion of the Series A marks a fast-moving year for Trogenix, which only emerged from stealth in November 2024. The ...

Through the FDA's ANDA scheme, drug manufacturers who test and produce their generic medicines on US soil can now seek ...

Health Canada has approved Santhera Pharmaceuticals’ Agamree (vamorolone) drug for treating Duchenne muscular dystrophy (DMD) ...

Researchers from McMaster University and MIT have discovered a new antibiotic to treat inflammatory bowel diseases (IBD).